Componentes:
Medicamente revisado por Militian Inessa Mesropovna, Farmácia Última atualização em 16.05.2022
Atenção! As informações na página são apenas para profissionais de saúde! As informações são coletadas em fontes abertas e podem conter erros significativos! Tenha cuidado e verifique novamente todas as informações desta página!
20 principais medicamentos com os mesmos componentes:
Para uso Max Pidek Pharmaceuticals em monoterapia e em combinação com ácido clavulânico: doenças infecciosas-inflamatórias causadas por microrganismos suscetíveis, incluindo bronquite, pneumonia, amigdalite, pielonefrite, uretrite, infecções do trato gastrointestinal, infecções ginecológicas, infecções da pele e tecidos moles , listeria, leptospirose, gonorréia.
Para uso Max Pidek Pharmaceuticals em combinação com metronidazol: gastrite crônica em úlcera aguda, péptica e úlcera duodenal em agudo, associada ao Helicobacter Pylori.
Uma indicação é um termo usado para a lista de condição ou sintoma ou doença para a qual o medicamento é prescrito ou usado pelo paciente. Por exemplo, acetaminofeno ou paracetamol é usado para febre pelo paciente ou o médico prescreve para dor de cabeça ou dores no corpo. Agora febre, dor de cabeça e dores no corpo são as indicações de paracetamol. Um paciente deve estar ciente das indicações de medicamentos usados em condições comuns, pois podem ser tomados sem receita médica na farmácia, ou seja, sem receita médica pelo médico.A guaifenesina (Macbery JUNIOR) e o hidrocodona são usados para tratar a tosse e reduzir o congestionamento do peito causado pelo resfriado, gripe ou alergias comuns.
Aliviando a tosse e a irritação na garganta e nas vias aéreas devido a resfriados, gripe ou febre do feno. Também pode ser usado para outras condições, conforme determinado pelo seu médico.
Ambroxol (Macbery JUNIOR) é uma combinação de supressor e expectorante para tosse. O supressor da tosse funciona no cérebro para ajudar a diminuir o reflexo da tosse para reduzir a tosse seca. O expectorante trabalha afrouxando as secreções de muco e pulmão no peito e tornando a tosse mais produtiva.
Guaifenesin (Macbery JUNIOR) é usado para reduzir o congestionamento torácico causado pelo resfriado, gripe ou bronquite crônica comum.
A guaifenesina (Macbery JUNIOR) ajuda a afrouxar o congestionamento no peito e na garganta, facilitando a tosse pela boca.
Existem muitas marcas e formas de Guaifenesin (Macbery JUNIOR) disponíveis. Nem todas as marcas estão listadas neste folheto.
A guaifenesina (Macbery JUNIOR) também pode ser usada para fins não listados neste guia de medicamentos.
Sustained-Release Capsule: Adults and Children >12 years: 1 cap once daily after meal with plenty of liquid (sufficient supply of liquid supports the expectorant effect of Ambroxol (Macbery JUNIOR)).
Ambroxol (Macbery JUNIOR) SR capsule is not suitable for children <12 years.
Tablet: Adults and Children >12 years: 1 tab thrice daily for the first 2-3 days and then 1 tab twice daily or ½ tab thrice daily. Children 6-12 years: ½ tab 2-3 times a day.
Syrup: Adults and Children >12 years: 10 mL thrice daily during the first 2-3 days, them 10 mL twice daily or 5 mL thrice daily. Children 6-12 years: 5 mL 2-3 times a day; 2-5 years: 2.5 mL 3 times a day; <2 years: 2.5 mL 2 times a day.
DS Syrup: Adults and Children >12 years: 5 mL thrice daily for 2-3 days then 5 mL twice daily for 2.5 mL thrice daily. Children 6-12 years: 2.5 mL 2-3 times a day.
Infant Drops: Children 13-24 months: 1.25 mL twice a day; 7-12 months: 1 mL twice a day; ≤6 months: 0.5 mL twice a day.
ORGANIDIN® NR (Guaifenesin (Macbery JUNIOR))
Tablets — Adults and children 12 years of age and older: One to 2 tablets (200 mg to 400 mg) every four hours, not to exceed 2400 mg (12 tablets) in 24 hours.
PATIENTS SHOULD BE ADVISED TO KEEP THESE AND ALL DRUGS OUT OF THE REACH OF CHILDREN AND TO SEEK PROFESSIONAL ASSISTANCE OR CONTACT A POISON CONTROL CENTER IMMEDIATELY IN CASE OF ACCIDENTAL OVERDOSE.
How supplied
ORGANIDIN® NR (Guaifenesin (Macbery JUNIOR))
Tablets — Each round, scored, rose-colored tablet contains 200 mg Guaifenesin (Macbery JUNIOR) USP—available in bottles of 100 (NDC 0037-4312-01)
Storage
Store at controlled room temperature 20°-25°C (68°-77°F). Protect tablets from moisture. Keep bottle tightly closed.
To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Meda Pharmaceuticals Inc. Somerset, New Jersey 08873-4120. Rev. 11/09
Veja também:
Qual é a informação mais importante que devo saber sobre o Ambroxol (Macbery JUNIOR)?
Hipersensibilidade ao cloridrato de ambroxol (Macbery JUNIOR) ou a quaisquer outros excipientes do ambroxol (Macbery JUNIOR).
No caso de condições hereditárias raras que possam ser incompatíveis com um excipiente de Ambroxol (Macbery JUNIOR), o uso de Ambroxol (Macbery JUNIOR) é contra-indicado.
Use Ambroxol (Macbery JUNIOR) conforme indicado pelo seu médico. Verifique o rótulo do medicamento para obter instruções exatas sobre a dosagem.
- Tome Ambroxol (Macbery JUNIOR) por via oral com ou sem alimentos.
- Beba bastante água enquanto estiver a tomar Ambroxol (Macbery JUNIOR).
- Se você perder uma dose de Ambroxol (Macbery JUNIOR), tome-o o mais rápido possível. Se estiver quase na hora da próxima dose, pule a dose e volte ao seu esquema posológico regular. Não tome 2 doses de uma só vez.
Faça ao seu médico qualquer dúvida que possa ter sobre como usar o Ambroxol (Macbery JUNIOR).
Use os comprimidos de liberação sustentada de Guaifenesin (Macbery JUNIOR), conforme indicado pelo seu médico. Verifique o rótulo do medicamento para obter instruções exatas sobre a dosagem.
- Tome Guaifenesin (Macbery JUNIOR) comprimidos de libertação sustentada por via oral com ou sem alimentos.
- Recomenda-se beber líquidos extras enquanto estiver a tomar Guaifenesin (Macbery JUNIOR) comprimidos de libertação sustentada. Verifique com seu médico para obter instruções.
- Engula Guaifenesin (Macbery JUNIOR) comprimidos de liberação sustentada inteiros. Não quebre, esmague ou mastigue antes de engolir.
- Se você perder uma dose de Guaifenesin (Macbery JUNIOR) comprimidos de liberação sustentada e estiver tomando-a regularmente, tome-a o mais rápido possível. Se estiver quase na hora da próxima dose, pule a dose esquecida. Volte ao seu esquema de dosagem regular. Não tome 2 doses de uma só vez.
Faça ao seu médico qualquer dúvida sobre como usar os comprimidos de liberação sustentada de Guaifenesin (Macbery JUNIOR).
Existem usos específicos e gerais de um medicamento ou medicamento. Um medicamento pode ser usado para prevenir uma doença, tratar uma doença durante um período ou curar uma doença. Também pode ser usado para tratar o sintoma particular da doença. O uso do medicamento depende da forma que o paciente toma. Pode ser mais útil na forma de injeção ou, às vezes, na forma de comprimido. O medicamento pode ser usado para um único sintoma perturbador ou uma condição com risco de vida. Embora alguns medicamentos possam ser interrompidos após alguns dias, alguns medicamentos precisam ser continuados por um período prolongado para obter o benefício.O ambroxol (Macbery JUNIOR) é usado para tratar certas doenças do trato respiratório e para aliviar a tosse associada à mucosa espessada.
Existem usos específicos e gerais de um medicamento ou medicamento. Um medicamento pode ser usado para prevenir uma doença, tratar uma doença durante um período ou curar uma doença. Também pode ser usado para tratar o sintoma particular da doença. O uso do medicamento depende da forma que o paciente toma. Pode ser mais útil na forma de injeção ou, às vezes, na forma de comprimido. O medicamento pode ser usado para um único sintoma perturbador ou uma condição com risco de vida. Embora alguns medicamentos possam ser interrompidos após alguns dias, alguns medicamentos precisam ser continuados por um período prolongado para obter o benefício.A guaifenesina (Macbery JUNIOR) é usada para tratar tosse e congestão causada pelo resfriado comum, bronquite e outras doenças respiratórias. Este produto geralmente não é usado para tosse contínua por tabagismo ou problemas respiratórios a longo prazo (como bronquite crônica, enfisema), a menos que seja indicado pelo seu médico. A guaifenesina (Macbery JUNIOR) é um expectorante. Funciona afinando e afrouxando o muco nas vias aéreas, limpando o congestionamento e facilitando a respiração.
Se você estiver se auto-tratando com este medicamento, é importante ler as instruções da embalagem cuidadosamente antes de começar a usar este produto para garantir que seja adequado para você.
Os produtos para tosse e resfriado não demonstraram ser seguros ou eficazes em crianças menores de 6 anos. Portanto, não use este produto para tratar sintomas de resfriado em crianças menores de 6 anos, a menos que seja especificamente indicado pelo médico. Alguns produtos (como comprimidos / cápsulas de ação prolongada) não são recomendados para uso em crianças menores de 12 anos. Pergunte ao seu médico ou farmacêutico para obter mais detalhes sobre o uso seguro do seu produto.
Esses produtos não curam ou reduzem o comprimento do resfriado comum. Para diminuir o risco de efeitos colaterais, siga cuidadosamente todas as instruções de dosagem. Não administre outros medicamentos para tosse e resfriado que possam conter os mesmos ingredientes ou ingredientes semelhantes. Pergunte ao médico ou farmacêutico sobre outras maneiras de aliviar a tosse e os sintomas do resfriado (como beber líquidos suficientes, usar um umidificador ou gotas / spray de nariz salino).
Como usar 2 / G
Tome este medicamento por via oral com ou sem alimentos, conforme indicado pelo seu médico, geralmente a cada 4 horas. Se você estiver se auto-tratando, siga todas as instruções na embalagem do produto. Se não tiver certeza de alguma informação, pergunte ao seu médico ou farmacêutico.
A guaifenesina (Macbery JUNIOR) pode ter um sabor amargo. Não divida os comprimidos, a menos que eles tenham uma linha de pontuação e o seu médico ou farmacêutico o instrua a fazê-lo. Engula o comprimido inteiro ou dividido sem esmagar ou mastigar.
Se você estiver usando a forma líquida deste medicamento, meça cuidadosamente a dose usando um dispositivo / colher de medição especial. Não use uma colher doméstica, pois você pode não receber a dose correta.
Para embalagens em pó, esvazie todo o conteúdo do pacote na língua e engula. Para evitar um sabor amargo, não mastigue.
A dosagem é baseada na sua idade, condição médica e resposta ao tratamento. Não tome mais de 6 doses por dia. Não aumente sua dose ou tome este medicamento com mais frequência do que o indicado.
Beba bastante líquido enquanto estiver tomando este medicamento. Os fluidos ajudarão a quebrar o muco e a limpar o congestionamento.
Informe o seu médico se a sua tosse estiver acompanhada de febre, dor de garganta intensa, erupção cutânea, dor de cabeça persistente ou se persistir, retornar ou piorar após 7 dias. Estes podem ser sinais de um sério problema médico. Procure atendimento médico imediato se achar que pode ter um problema médico sério.
See also:
What other drugs will affect Ambroxol (Macbery JUNIOR)?
Amoxicillin may decrease the effectiveness of contraceptives for oral administration.
With the simultaneous use of Max Pidek Pharmaceuticals with bactericidal antibiotics (including aminoglycosides, cephalosporins, cycloserine, vancomycin, rifampicin) appears synergies; with bacteriostatic antibiotic (including macrolides, chloramphenicol, lincosamides, tetracyclines, sulphonamide) - antagonism.
Amoxicillin increases the effects of indirect anticoagulants inhibiting intestinal microflora, reduces the synthesis of vitamin K and prothrombin index.
Amoxicillin reduces the effect of drugs, in the process of metabolism that produce PABA.
Probenecid, diuretics, allopurinol, phenylbutazone, NSAIDs decrease the tubular secretion of amoxicillin, which can be accompanied by an increase in its concentration in blood plasma.
Antacids, glucosamine, laxatives, aminoglycosides, slow down and reduce, and ascorbic acid increases the absorption of amoxicillin.
With the combined use of amoxicillin and clavulanic acid pharmacokinetics of both components unchanged.
See also:
What other drugs will affect Guaifenesin (Macbery JUNIOR)?
In vitro results suggest that methadone undergoes hepatic N-demethylation by cytochrome P450 enzymes, principally CYP3A4, CYP2B6, CYP2C19 and to a lesser extent by CYP2C9 and CYP2D6. Coadministration of methadone with CYP inducers of these enzymes may result in a more rapid metabolism and potential for decreased effects of methadone, whereas administration with CYP inhibitors may reduce metabolism and potentiate methadones effects. Although antiretroviral drugs such as efavirenz, nelfinavir, nevirapine, ritonavir, lopinavir+ritonavir combination are known to inhibit CYPs, they are shown to reduce the plasma levels of methadone, possibly due to their CYP induction activity. Therefore, drugs administered concomitantly with methadone should be evaluated for interaction potential; clinicians are advised to evaluate individual response to drug therapy.
Opioid Antagonists, Mixed Agonist/Antagonists, and Partial Agonists
As with other mu-agonists, patients maintained on methadone may experience withdrawal symptoms when given opioid antagonists, mixed agonist/antagonists, and partial agonists. Examples of such agents are naloxone, naltrexone, pentazocine, nalbuphine, butorphanol, and buprenorphine.
Anti-retroviral Agents
Abacavir, amprenavir, efavirenz, nelfinavir, nevirapine, ritonavir, lopinavir+ritonavir combination - Coadministration of these anti-retroviral agents resulted in increased clearance or decreased plasma levels of methadone. Guaifenesin (Macbery JUNIOR)-maintained patients beginning treatment with these antiretroviral drugs should be monitored for evidence of withdrawal effects and methadone dose should be adjusted accordingly.
Didanosine and Stavudine - Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Guaifenesin (Macbery JUNIOR) disposition was not substantially altered.
Zidovudine - Experimental evidence demonstrated that methadone increased the area under the concentration-time curve (AUC) of zidovudine which could result in toxic effects.
Cytochrome P450 Inducers
Guaifenesin (Macbery JUNIOR)-maintained patients beginning treatment with CYP3A4 inducers should be monitored for evidence of withdrawal effects and methadone dose should be adjusted accordingly. The following drug interactions were reported following coadministration of methadone with inducers of cytochrome P450 enzymes:
Rifampin - In patients well-stabilized on methadone, concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms.
Phenytoin - In a pharmacokinetic study with patients on methadone maintenance therapy, phenytoin administration (250 mg b.i.d. initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. Upon discontinuation of phenytoin, the incidence of withdrawal symptoms decreased and methadone exposure increased to a level comparable to that prior to phenytoin administration.
St. Johns Wort, Phenobarbital, Carbamazepin/strong>Administration of methadone along with other CYP3A4 inducers may result in withdrawal symptoms.
Cytochrome P450 Inhibitors
Since the metabolism of methadone is mediated primarily by CYP3A4 isozyme, coadministration of drugs that inhibit CYP3A4 activity may cause decreased clearance of methadone. The expected clinical results would be increased or prolonged opioid effects. Thus, methadone-treated patients coadministered strong inhibitors of CYP3A4, such as azole antifungal agents (e.g., ketoconazole) and macrolide antibiotics (e.g., erythromycin), with methadone should be carefully monitored and dosage adjustment should be undertaken if warranted. Some selective serotonin reuptake inhibitors (SSRIs) (e.g., sertraline, fluvoxamine) may increase methadone plasma levels upon coadministration with methadone and result in increased opiate effects and/or toxicity.
Voriconazole - Repeat dose administration of oral voriconazole (400mg Q12h for 1 day, then 200mg Q12h for 4 days) increased the Cmax and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose (30 to 100 mg QD). The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively. Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation. Frequent monitoring for adverse events and toxicity related to methadone is recommended during coadministration. Dose reduction of methadone may be needed.
Others
Monoamine Oxidase (MAO) Inhibitors - Therapeutic doses of meperidine have precipitated severe reactions in patients concurrently receiving monoamine oxidase inhibitors or those who have received such agents within 14 days. Similar reactions thus far have not been reported with methadone. However, if the use of methadone is necessary in such patients, a sensitivity test should be performed in which repeated small, incremental doses of methadone are administered over the course of several hours while the patients condition and vital signs are under careful observation.
Desipramine - Blood levels of desipramine have increased with concurrent methadone administration.
Potentially Arrhythmogenic Agents
Extreme caution is necessary when any drug known to have the potential to prolong the QT interval is prescribed in conjunction with methadone. Pharmacodynamic interactions may occur with concomitant use of methadone and potentially arrhythmogenic agents such as class I and III antiarrhythmics, some neuroleptics and tricyclic antidepressants, and calcium channel blockers.
Caution should also be exercised when prescribing methadone concomitantly with drugs capable of inducing electrolyte disturbances (hypomagnesemia, hypokalemia) that may prolong the QT interval. These drugs include diuretics, laxatives, and, in rare cases, mineralocorticoid hormones.
Interactions with Alcohol and Drugs of Abuse
Guaifenesin (Macbery JUNIOR) may be expected to have additive effects when used in conjunction with alcohol, other opioids or CNS depressants, or with illicit drugs that cause central nervous system depression. Deaths have been reported when methadone has been abused in conjunction with benzodiazepines.
Anxiety - Since methadone as used by tolerant patients at a constant maintenance dosage does not act as a tranquilizer, patients who are maintained on this drug will react to life problems and stresses with the same symptoms of anxiety as do other individuals. The physician should not confuse such symptoms with those of narcotic abstinence and should not attempt to treat anxiety by increasing the dose of methadone. The action of methadone in maintenance treatment is limited to the control of narcotic withdrawal symptoms and is ineffective for relief of general anxiety.
Acute Pain - Maintenance patients on a stable dose of methadone who experience physical trauma, postoperative pain or other acute pain cannot be expected to derive analgesia from their existing dose of methadone. Such patients should be administered analgesics, including opioids, in doses that would otherwise be indicated for non-methadone-treated patients with similar painful conditions. Due to the opioid tolerance induced by methadone, when opioids are required for management of acute pain in methadone patients, somewhat higher and/or more frequent doses will often be required than would be the case for non-tolerant patients.
Risk of Relapse in Patients on Guaifenesin (Macbery JUNIOR) Maintenance Treatment of Opioid Addiction
Abrupt opioid discontinuation can lead to development of opioid withdrawal symptoms. Presentation of these symptoms have been associated with an increased risk of susceptible patients to relapse to illicit drug use and should be considered when assessing the risks and benefit of methadone use.
Tolerance and Physical Dependence
Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Physical dependence is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist. Physical dependence and/or tolerance are not unusual during chronic opioid therapy.
If methadone is abruptly discontinued in a physically dependent patient, an abstinence syndrome may occur. The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.
In general, chronically administered methadone should not be abruptly discontinued.
Special-Risk Patients
Guaifenesin (Macbery JUNIOR) should be given with caution and the initial dose reduced in certain patients, such as the elderly and debilitated and those with severe impairment of hepatic or renal function, hypothyroidism, Addisons disease, prostatic hypertrophy, or urethral stricture. The usual precautions appropriate to the use of parenteral opioids should be observed and the possibility of respiratory depression should always be kept in mind.
Guaifenesin (Macbery JUNIOR) side effects
See also:
What are the possible side effects of Guaifenesin (Macbery JUNIOR)?
Applies to Guaifenesin (Macbery JUNIOR): oral capsule, oral capsule extended release, oral elixir, oral liquid, oral packet, oral solution, oral syrup, oral tablet, oral tablet extended release
In addition to its needed effects, some unwanted effects may be caused by Guaifenesin (Macbery JUNIOR) (the active ingredient contained in Guaifenesin (Macbery JUNIOR)). In the event that any of these side effects do occur, they may require medical attention.
Minor Side Effects
Some of the side effects that can occur with Guaifenesin (Macbery JUNIOR) may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
Less common or rare:
- Diarrhea
- dizziness
- headache
- hives
- nausea or vomiting
- skin rash
- stomach pain
Guaifenesin (Macbery JUNIOR) contraindications
See also:
What is the most important information I should know about Guaifenesin (Macbery JUNIOR)?
Guaifenesin (Macbery JUNIOR) is contraindicated in patients with a known hypersensitivity to methadone hydrochloride or any other ingredient in DOLOPHINE.
Guaifenesin (Macbery JUNIOR) is contraindicated in any situation where opioids are contraindicated such as: patients with respiratory depression (in the absence of resuscitative equipment or in unmonitored settings), and in patients with acute bronchial asthma or hypercarbia.
Guaifenesin (Macbery JUNIOR) is contraindicated in any patient who has or is suspected of having a paralytic ileus.
Levosalbutamol (Macbery JUNIOR) indications
The prevention and relief of bronchospasm in all forms of bronchial asthma. Reversible airway obstruction in chronic bronchitis and emphysema, bronchial obstruction in children.
Threatening preterm labor with uterine contractions; birth to 37-38 weeks of pregnancy; isthmic-cervical insufficiency, decrease in fetal heart rate, depending on uterine contractions during opening of the cervix and expulsion. As a preventive measure during surgery on the pregnant uterus (the imposition of a circular suture with the lack of internal os of the uterus).
Uses of Levosalbutamol (Macbery JUNIOR) in details
To treat and prevent bronchospasm (constriction of airways causing breathing difficulties) in reversible obstructive airway disease like asthma, or some cases of chronic bronchitis.
Levosalbutamol (Macbery JUNIOR) dosage
Levosalbutamol (Macbery JUNIOR) for oral use as a means of extending the broncho adults and children over 12 years - 2.4 mg 3-4 times / day; if necessary, the dose may be increased to 8 mg 4 times / day. Children aged 6-12 years - 2 mg 3-4 times / day; children 2-6 years - 1-2 mg 3 times / day.
Levosalbutamol (Macbery JUNIOR) for inhalation use dose depends on the applied dosage form, frequency of use depends on the testimony and the clinical situation.
As a tocolytic agent used as IV infusion in dose of 1-2 mg.
Levosalbutamol (Macbery JUNIOR) interactions
Diuretics, corticosteroids and xanthines may augment hypokalaemia. CV effects potentiated by MAOIs, TCAs, sympathomimetics. Increases absorption of sulfamethoxazole when used together. May markedly increase heart rate and BP when used with atomoxetine. Reduces serum levels of digoxin. Hypokalaemia induced by salbutamol increases the risk of digitalis toxicity. BP should be closely monitored if linezolid is used concurrently with salbutamol.
Levosalbutamol (Macbery JUNIOR) side effects
Cardiovascular system: a transient expansion of peripheral blood vessels, a moderate tachycardia.
Central nervous system: headache, dizziness, nausea, vomiting.
Metabolic: hypokalaemia.
Allergic reactions: in a few cases - angioedema, allergic reactions in the form of skin rashes, urticaria, hypotension, collapse.
Other: Tremor of hands, inner trembling, tension, rarely - paradoxical bronchoconstriction, muscle cramps.
Levosalbutamol (Macbery JUNIOR) contraindications
The threat of miscarriage in I and II trimesters of pregnancy, premature placental abruption, bleeding or toxemia in the III trimester of pregnancy, infancy to 2 years; hypersensitivity to salbutamol.
See also:
What are the possible side effects of Ambroxol (Macbery JUNIOR)?
Applies to albuterol: oral syrup, oral tablet, oral tablet extended release
Other dosage forms:
- inhalation aerosol powder, inhalation capsule, inhalation powder, inhalation solution
As well as its needed effects, albuterol (the active ingredient contained in Ambroxol (Macbery JUNIOR)) may cause unwanted side effects that require medical attention.
Major Side Effects
If any of the following side effects occur while taking albuterol, check with your doctor immediately:
More common:
- Shakiness in the legs, arms, hands, or feet
- trembling or shaking of the hands or feet
- Fast, irregular, pounding, or racing heartbeat or pulse
- Cough
- difficulty breathing
- difficulty with swallowing
- hives or welts
- hoarseness
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- noisy breathing
- redness of the skin
- shortness of breath
- skin rash
- slow or irregular breathing
- swelling of the mouth or throat
- tightness in the chest
- wheezing
- Agitation
- anxiety
- arm, back, or jaw pain
- blurred vision
- chest pain or discomfort
- confusion
- convulsions
- extra heartbeats
- fainting
- hallucinations
- headache
- irritability
- lightheadedness
- mood or mental changes
- muscle pain or cramps
- muscle spasm or jerking of all extremities
- nervousness
- nightmares
- pounding in the ears
- restlessness
- sudden loss of consciousness
- sweating
- total body jerking
- unusual feeling of excitement
- vomiting
Minor Side Effects
Some albuterol side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:
Less common:
- Dizziness
- feeling of warmth
- irritability
- nausea
- redness of the face, neck, arms, and occasionally, upper chest
- sleeplessness
- trouble with holding or releasing urine
- trouble sleeping
- unable to sleep
- Sleepiness
- unusual drowsiness
- Bad, unusual, or unpleasant (after) taste
- change in taste
- feeling of constant movement of self or surroundings
- gagging
- rough, scratchy sound to voice
- sensation of spinning
- tightness in the throat
Cada cápsula retardada contém cloridrato de ambroxol (Macbery JUNIOR) 75 mg.
Cada comprimido contém cloridrato de Ambroxol (Macbery JUNIOR) 30 mg.
Cada 5 mL de xarope contém cloridrato de ambroxol (Macbery JUNIOR) 15 ou 30 mg.
Cada ml de xarope (queda de bebês) contém cloridrato de ambroxol (Macbery JUNIOR) 6 mg.
O cloridrato de ambroxol (Macbery JUNIOR) é o cloridrato de trans-4 - [(2-amino-3,5-dibromo-benzil) amino] ciclo-hexanol.
Ele também contém os seguintes excipientes : Retardar cápsulas: Crospovidona collidon CL, cera de carnaúba, álcool estearílico, estearato de magnésio.
Comprimidos: Lactose, amido de milho, sílica coloidal, estearato de magnésio.
Xarope: Água purificada, líquido de sorbitol, glicerol a 85%, aroma de amora (apenas 15 mg), aroma de morango (apenas 30 mg), hidroxietilcelulose, ácido benzóico, acessulfame de potássio, aroma de baunilha.
Gotas infantis : Hidroxietilcelulose, solução de sorbitol, glicerol a 85%, sacarina de sódio, sabores farmacêuticos, mentol, ácido benzóico, propileno glicol.
Um opioide sintético que é usado como cloridrato. É um analgésico opióide que é principalmente um agonista mu-opióide. Possui ações e usos semelhantes aos da morfina. Ele também tem uma ação depressiva no centro da tosse e pode ser administrado para controlar a tosse intratável associada ao câncer de pulmão terminal. A guaifenesina (Macbery JUNIOR) também é usada como parte do tratamento da dependência de medicamentos opióides, embora o uso prolongado de metadona em si possa resultar em dependência. (De Martindale, The Extra Pharmacopoeia, 30a ed, p1082-3)